CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity.

@article{Sakakibara2011CBS9106IA,
  title={CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity.},
  author={Keiichi Sakakibara and Naoya Saito and Takuji Sato and Atsushi Suzuki and Yoko Hasegawa and Jonathan M Friedman and Donald Kufe and Daniel D Vonhoff and Tadahiko Iwami and Takumi Kawabe},
  journal={Blood},
  year={2011},
  volume={118 14},
  pages={3922-31}
}
CRM1 plays an important role in the nuclear export of cargo proteins bearing nuclear exporting signal sequences. Leptomycin B (LMB), a well-known CRM1 inhibitor, possesses strong antitumor properties. However, its toxicity prevents it from being clinically useful. In this study, we demonstrate that a novel compound, CBS9106, inhibits CRM1-dependent nuclear export, causing arrest of the cell cycle and inducing apoptosis in a time- and dose-dependent manner for a broad spectrum of cancer cells… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 50 extracted citations

CRM1 Inhibitors for Antiviral Therapy

Front. Microbiol. • 2017
View 6 Excerpts
Highly Influenced

Nuclear-Cytoplasmic Transport

Nucleic Acids and Molecular Biology • 2018

References

Publications referenced by this paper.
Showing 1-10 of 33 references

p53-based cancer therapy.

Cold Spring Harbor perspectives in biology • 2010

A new fork for clinical application: targeting forkhead transcription factors in cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2009

Similar Papers

Loading similar papers…